The dust has settled at Biogen following the company’s disastrous announcement that it was ending development of Alzheimer’s drug aducanumab, and in its latest Q1 figures the company hoped
The European drug regulator has called for a review of Sanofi’s multiple sclerosis drug Lemtrada following reports of immune-related conditions and sometimes fatal problems with the heart a
Merck KGaA has finally claimed an FDA approval for its oral multiple sclerosis therapy Mavenclad, eight years after being turned down by the US regulator.
The FDA has approved Novartis’ Mayzent (siponimod) multiple sclerosis pill for relapsing forms of the disease, dealing a potential blow to a much-delayed rival from Celgene.
Celgene has filed its highly anticipated oral MS drug ozanimod with the US regulator, more than a year after the FDA rejected it because of a bureaucratic foul-up.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
